464280 — TDSPharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapContrarian

Annual income statement for TDSPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	19,820	25,588	30,049	27,519	27,621
Cost of Revenue
Gross Profit	3,987	6,167	7,941	7,722	7,504
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	17,505	21,860	25,033	23,789	23,856
Operating Profit	2,314	3,728	5,016	3,730	3,765
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,419	3,846	5,489	4,212	4,973
Provision for Income Taxes
Net Income After Taxes	2,063	3,456	4,688	3,718	4,275
Net Income Before Extraordinary Items
Net Income	2,063	3,456	4,688	3,718	4,275
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,063	3,456	4,688	3,718	4,275
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	431	730	979	820	724
Dividends per Share